Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Neurology · Progressive Supranuclear Palsy - Richardson Syndrome

Validation & Orientation: Understanding a PSP-RS Diagnosis

At a Glance

Progressive Supranuclear Palsy - Richardson Syndrome (PSP-RS) is a rare neurological condition caused by the buildup of tau protein in the brain. Though often misdiagnosed as Parkinson's initially, PSP-RS has distinct signs like early frequent falls and difficulty moving the eyes.

Receiving a diagnosis of Progressive Supranuclear Palsy - Richardson Syndrome (PSP-RS) often marks the end of a long and exhausting journey [1]. Because this condition is rare and its early symptoms frequently mimic other disorders, many people spend years seeking answers, often receiving an initial diagnosis of Parkinson’s disease [2][3]. Validating the frustration of that “diagnostic odyssey” is the first step toward moving forward with a clear understanding of your health.

Why the Diagnosis is Often Delayed

It is common for local doctors to initially mistake PSP-RS for Parkinson’s disease [1]. In the early stages, both conditions can cause stiffness, slow movement, and balance issues [4]. However, PSP-RS is much rarer, affecting approximately 5 to 7 people per 100,000 [5].

Because general neurologists see hundreds of Parkinson’s patients for every one PSP patient, they are trained to look for Parkinson’s first [2]. The “classic” signs of PSP-RS, such as vertical supranuclear gaze palsy (difficulty moving the eyes up or down) and early frequent falls, may not appear until the disease has progressed for some time [6][7].

Three Stabilizing Facts

When processing this news, keep these three foundational facts in mind:

  1. It is a specific biological process, not a mystery. PSP-RS is caused by the buildup of a protein called tau in the brain [8]. While this is challenging news, having a specific diagnosis means you can now stop searching for answers and start focusing on the specialized care that targets your specific symptoms [9].
  2. It is NOT Parkinson’s Disease. While they share some “parkinsonian” symptoms, the underlying cause is different [1]. This is why medications that help Parkinson’s patients, like levodopa, typically provide little to no relief for people with PSP-RS [10]. Understanding this helps you and your care team avoid treatments that won’t work and focus on those that do [11].
  3. Diagnosis is more accurate than ever. Recent updates to diagnostic standards, specifically the 2017 Movement Disorder Society criteria, allow doctors to identify PSP-RS with much higher certainty than in the past [12][13]. Specialists can also use MRI to look for midbrain atrophy (shrinking of a specific part of the brain), which helps distinguish PSP-RS from other conditions [14][15].

Understanding “4R Tauopathy”

You may hear your doctor refer to PSP-RS as a 4R tauopathy. This term describes the internal “machinery” of the disease:

  • Tau is a protein that normally helps stabilize the internal structure of brain cells [8].
  • In PSP-RS, this protein misfolds and clumps together, becoming toxic [16].
  • 4R refers to “4-repeat,” a specific chemical structure of the tau protein [8].

In 4R tauopathies, these toxic clumps primarily damage neurons and support cells in the brain regions responsible for balance and eye movement [17][18]. Knowing this specific “fingerprint” is vital because researchers are currently developing new therapies that specifically target this 4R tau protein to clear it from the brain [19][20]. Engaging with advocacy groups like CurePSP or checking registries like clinicaltrials.gov can connect you to these emerging research opportunities.

Next Steps for Care

While there is currently no cure, there is a clear path for managing the condition and improving quality of life:

  • Specialized Therapy: Structured exercise and physical therapy are beneficial for maintaining functionality and safety [11].
  • Symptom Monitoring: Standardized tools like the PSP Rating Scale help doctors track your progress and adjust care as needed [9][21].
  • Mental Health Support: Apathy and depression are common biological symptoms of PSP-RS, not just emotional reactions to the diagnosis, and they can be treated [22][23].

Common questions in this guide

Why is PSP-RS often misdiagnosed as Parkinson's disease?
In the early stages, both conditions cause stiffness, slow movement, and balance issues. Because Parkinson's is much more common, doctors often look for it first before the classic signs of PSP-RS, such as eye movement issues, become apparent.
What does it mean that PSP-RS is a 4R tauopathy?
A 4R tauopathy is a condition where a specific protein called tau misfolds and clumps together in the brain. In PSP-RS, these toxic clumps damage the specific areas of the brain responsible for balance and eye movement.
Can Parkinson's medications like levodopa treat my PSP-RS symptoms?
No. Medications like levodopa that help Parkinson's patients typically provide little to no relief for people with PSP-RS. This lack of response to levodopa actually helps doctors confirm a PSP-RS diagnosis.
How does an MRI help diagnose PSP-RS?
Specialists can use an MRI to look for midbrain atrophy, which is the shrinking of a specific part of the brain. Seeing this unique physical change on a scan helps distinguish PSP-RS from other neurological conditions.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my diagnosis based on the 2017 Movement Disorder Society (MDS) criteria?
  2. 2.Can you explain why my MRI results, specifically the size of my midbrain, support a PSP-RS diagnosis over Parkinson's?
  3. 3.What specific '4R' tau features led you to this diagnosis rather than a different tauopathy?
  4. 4.Given that I may have been misdiagnosed with Parkinson's in the past, what specific signs should I look for that indicate my condition is progressing differently?
  5. 5.Can we discuss a 'levodopa challenge' to see if there is any benefit, or to further confirm the lack of response typical in PSP-RS?
  6. 6.Are there specific clinical trials targeting 4R tau that I might be eligible to join?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Tau in Atypical Parkinsonisms: A Meta-Analysis of in Vivo PET Imaging Findings.

    Mena AM, Chen R, Graff-Guerrero A, et al.

    Movement disorders clinical practice 2023; (10(12)):1725-1737 doi:10.1002/mdc3.13885.

    PMID: 38094644
  2. 2

    Development and Validation of Automated Magnetic Resonance Parkinsonism Index 2.0 to Distinguish Progressive Supranuclear Palsy-Parkinsonism From Parkinson's Disease.

    Quattrone A, Bianco MG, Antonini A, et al.

    Movement disorders : official journal of the Movement Disorder Society 2022; (37(6)):1272-1281 doi:10.1002/mds.28992.

    PMID: 35403258
  3. 3

    Methods and utility of quantitative brainstem measurements in progressive supranuclear palsy versus Parkinson's disease in a routine clinical setting.

    Cooperrider J, Bluett B, Jones SE

    Clinical parkinsonism & related disorders 2020; (3()):100033 doi:10.1016/j.prdoa.2020.100033.

    PMID: 34316619
  4. 4

    "One line": A method for differential diagnosis of parkinsonian syndromes.

    Sako W, Abe T, Haji S, et al.

    Acta neurologica Scandinavica 2019; (140(3)):229-235 doi:10.1111/ane.13136.

    PMID: 31225648
  5. 5

    Which ante mortem clinical features predict progressive supranuclear palsy pathology?

    Respondek G, Kurz C, Arzberger T, et al.

    Movement disorders : official journal of the Movement Disorder Society 2017; (32(7)):995-1005 doi:10.1002/mds.27034.

    PMID: 28500752
  6. 6

    Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches.

    Boxer AL, Yu JT, Golbe LI, et al.

    The Lancet. Neurology 2017; (16(7)):552-563 doi:10.1016/S1474-4422(17)30157-6.

    PMID: 28653647
  7. 7

    Progressive spasticity, supranuclear gaze palsy and postural instability, without parkinsonism: what's in a phenotype?

    Ricciardi L, Edwards MJ, Fasano A, et al.

    Journal of the neurological sciences 2018; (390()):84-86 doi:10.1016/j.jns.2018.04.016.

    PMID: 29801913
  8. 8

    4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration.

    Saijo E, Metrick MA, Koga S, et al.

    Acta neuropathologica 2020; (139(1)):63-77 doi:10.1007/s00401-019-02080-2.

    PMID: 31616982
  9. 9

    A 15-Item modification of the PSP rating scale to improve clinical meaningfulness and statistical performance.

    Dam T, Yang L, Gillis C, et al.

    Nature communications 2025; (16(1)):414 doi:10.1038/s41467-024-55442-0.

    PMID: 39762226
  10. 10

    Phenotypic Spectrum of Progressive Supranuclear Palsy: Clinical Study and Apolipoprotein E Effect.

    Nasri A, Sghaier I, Neji A, et al.

    Journal of movement disorders 2024; (17(2)):158-170 doi:10.14802/jmd.23178.

    PMID: 38290492
  11. 11

    Physiotherapy case reports on three people with progressive supranuclear palsy.

    Mateus M, Castro Caldas A

    Frontiers in aging neuroscience 2023; (15()):1294293 doi:10.3389/fnagi.2023.1294293.

    PMID: 38145087
  12. 12

    Graphic Summary of Movement Disorders Society Criteria for Progressive Supranuclear Palsy and Multiple Allocations eXtinction Rules.

    Ogawa T, Hatano T, Oyama G, et al.

    Movement disorders clinical practice 2020; (7(2)):240-242 doi:10.1002/mdc3.12894.

    PMID: 32071951
  13. 13

    An Evaluation of the Progressive Supranuclear Palsy Speech/Language Variant.

    Whitwell JL, Stevens CA, Duffy JR, et al.

    Movement disorders clinical practice 2019; (6(6)):452-461 doi:10.1002/mdc3.12796.

    PMID: 31392246
  14. 14

    Accuracy of MR markers for differentiating Progressive Supranuclear Palsy from Parkinson's disease.

    Zanigni S, Calandra-Buonaura G, Manners DN, et al.

    NeuroImage. Clinical 2016; (11()):736-742 doi:10.1016/j.nicl.2016.05.016.

    PMID: 27330973
  15. 15

    Midbrain atrophy in patients with presymptomatic progressive supranuclear palsy-Richardson's syndrome.

    Ahn JH, Kim M, Kim JS, et al.

    Parkinsonism & related disorders 2019; (66()):80-86 doi:10.1016/j.parkreldis.2019.07.009.

    PMID: 31307918
  16. 16

    A critical appraisal of tau-targeting therapies for primary and secondary tauopathies.

    Imbimbo BP, Ippati S, Watling M, Balducci C

    Alzheimer's & dementia : the journal of the Alzheimer's Association 2022; (18(5)):1008-1037 doi:10.1002/alz.12453.

    PMID: 34533272
  17. 17

    Neuronal and oligodendroglial, but not astroglial, tau translates to in vivo tau PET signals in individuals with primary tauopathies.

    Slemann L, Gnörich J, Hummel S, et al.

    Acta neuropathologica 2024; (148(1)):70 doi:10.1007/s00401-024-02834-7.

    PMID: 39580770
  18. 18

    Histologic lesion type correlates of magnetic resonance imaging biomarkers in four-repeat tauopathies.

    Carlos AF, Tosakulwong N, Weigand SD, et al.

    Brain communications 2022; (4(3)):fcac108 doi:10.1093/braincomms/fcac108.

    PMID: 35663380
  19. 19

    Progressive supranuclear palsy: Neuropathology, clinical presentation, diagnostic challenges, management, and emerging therapies.

    DeRosier F, Hibbs C, Alessi K, et al.

    Disease-a-month : DM 2024; (70(8)):101753 doi:10.1016/j.disamonth.2024.101753.

    PMID: 38908985
  20. 20

    Open-Label Phase 1 Futility Studies of Salsalate and Young Plasma in Progressive Supranuclear Palsy.

    VandeVrede L, Dale ML, Fields S, et al.

    Movement disorders clinical practice 2020; (7(4)):440-447 doi:10.1002/mdc3.12940.

    PMID: 32373661
  21. 21

    Reply to: "Brief Clinical Rating Scales Should Not Be Overlooked".

    Respondek G, Piot I, Höglinger GU

    Movement disorders : official journal of the Movement Disorder Society 2020; (35(10)):1886 doi:10.1002/mds.28273.

    PMID: 33068467
  22. 22

    The Impact of Neuropsychiatric Symptoms in Perceived Quality of Life in Patients With Progressive Supranuclear Palsy.

    Morales-Rivero A, Garcia-Cordero I, Khoja A, et al.

    European journal of neurology 2025; (32(6)):e70248 doi:10.1111/ene.70248.

    PMID: 40525323
  23. 23

    Depression and Apathy across Different Variants of Progressive Supranuclear Palsy.

    Bower SM, Weigand SD, Ali F, et al.

    Movement disorders clinical practice 2022; (9(2)):212-217 doi:10.1002/mdc3.13396.

    PMID: 35146060

This page provides educational information about understanding a PSP-RS diagnosis. It does not replace professional medical advice, and you should always consult your neurologist regarding your symptoms and care plan.

Get notified when new evidence is published on Classic progressive supranuclear palsy syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.